ZALTRAP® (aflibercept)

Drug ZALTRAP® aflibercept Zaltrap Overview This is a summary of the European public assessment report (EPAR) for Zaltrap. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Zaltrap. For practical information about using Zaltrap, […]

STIVARGA® (regorafenib)

Drug STIVARGA® regorafenib Stivarga Overview This is a summary of the European public assessment report (EPAR) for Stivarga. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Stivarga. For practical information about using Stivarga, […]

VECTIBIX® (panitumumab)

Drug VECTIBIX® Pembrolizumab Vectibix Overview This is a summary of the European Public Assessment Report (EPAR) for Vectibix. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vectibix. For practical information about using Vectibix, […]

MVASI® (bevacizumab)

Drug MVASI® Bevacizumab Mvasi Overview This is a summary of the European public assessment report (EPAR) for Mvasi. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Mvasi. For practical information about using Mvasi, […]

LONSURF® (trifluridine / tipiracil)

Drug LONSURF® trifluridine / tipiracil Lonsurf Overview Lonsurf is a medicine used to treat adults with colorectal cancer (cancer of the large bowel) and gastric (stomach) cancer. It is used when the cancer is metastatic (has spread to other parts of the body) in patients who have already been treated with, or who cannot be […]

YERVOY® (ipilimumab)

Drug YERVOY® ipilimumab Yervoy Overview Yervoy is a cancer medicine used in adults and adolescents from 12 years of age with advanced melanoma (a type of skin cancer) and in adults with advanced renal cell carcinoma (a kidney cancer). Yervoy is usually used in combination with another medicine, nivolumab, but can also be used on […]

CYRAMZA® (ramucirumab)

Drug CYRAMZA® ramucirumab Cyramza Overview Cyramza is a cancer medicine used to treat adult patients with: advanced gastric cancer (cancer of the stomach) or cancer of the area where the gullet (oesophagus) enters the stomach (known as gastro-oesophageal junction adenocarcinoma). Cyramza is used in combination with another medicine, paclitaxel, or on its own if the […]

ERBITUX® (cetuximab)

Drug ERBITUX® cetuximab Erbitux Overview This is a summary of the European public assessment report (EPAR) for Erbitux. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Erbitux. How is Erbitux used? Erbitux should only […]

AVASTIN® (bevacizumab)

Drug AVASTIN® bevacizumab Avastin Overview This is a summary of the European public assessment report (EPAR) for Avastin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Avastin. For practical information about using Avastin, […]

XELODA® (capecitabine)

Drug XELODA® capecitabine Xeloda Overview Xeloda is a cancer medicine that is used to treat: colon (large bowel) cancer. Xeloda is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes’ stage C colon cancer; metastatic colorectal cancer (cancer of the large bowel that has […]